Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
January 19 2022 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that C. Russell Trenary
III, President & Chief Executive Officer will participate in
the Virtual Investor 2022 Top Picks Conference on
Tuesday, January 25, 2022 at 3:00 PM ET.
As part of the virtual event, Outlook
Therapeutics will provide a corporate presentation, followed by a
moderated interactive Q&A session. In addition to the moderated
portion of the event, all investors and interested parties will
have the opportunity to submit questions live during the event.
Interested parties may also pre-submit questions in advance of the
live event, which can be sent via the conference website at
virtualinvestorco.com. The Company will answer as many questions as
possible during the event.
A live video webcast of the presentation will be
available on the Events page of the Investors section of Outlook
Therapeutics’ website (outlooktherapeutics.com). A webcast replay
will be available two hours following the live presentation and
will be accessible for one year.About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024